ESMO Media Releases

Creation of CMO role reflects ESMO’s rapid growth and follows extensive six-month selection process

On World Cancer Day, ESMO puts cancer patients centre stage by organising a workshop dedicated to exploring ways that advocacy networks can drive research

ESMO announces the appointment of Keith Hanson McGregor as their new CEO. Dr McGregor is currently ESMO’s Chief Operating Officer.

KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1%

LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib

Promising results of PALOMA3 trial confirmed in Asian patients

Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer.  Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study

Underprivileged patients are at major risk of disease-related “financial catastrophe", study in eight low- and middle-income Southeast Asian countries shows

LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.

CheckMate 017 clearly showed that the checkpoint inhibitor improves the overall health status in patients with advanced squamous non-small-cell lung cancer

Two drugs are changing the current landscape for the treatment of advanced renal cell carcinoma

Cancer is distressing for patients and families, and supportive care is today an important part of therapy